Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Mar 30;27(15):2542–2552. doi: 10.1200/JCO.2008.19.9356

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 by American Society of Clinical Oncology

PMC Copyright notice

Fig 4. — Cediranib decreases vessel diameter at early time points and decreases vessel density at later time points. (A, B) Representative multiphoton laser scanning microscopic (MPLSM) three-dimensional reconstruction of the tumor (white) and peritumor vessels (gray) showing the effects of (A) control versus (B) cediranib treatment on vessel diameter. (C) Cediranib transiently but significantly decreases vessel diameter measured by MPLSM (*P < .05, n = 4). (D) Cediranib significantly decreases vessel density (length) measured by MPLSM (*P < .05, n = 4). (E) Cediranib decreases vessel diameter at the tumor margin at day 2 (measured by immunostaining for CD31 endothelial staining; *P < .05, n = 9). (F) Cediranib decreases microvascular density at the tumor center at day 8 (measured by immunostaining for CD31; *P < .05, n = 9).